Legacy Capital Group California Inc. Lowers Stock Holdings in Bruker Corporation $BRKR

Legacy Capital Group California Inc. lessened its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 41.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,948 shares of the medical research company’s stock after selling 9,247 shares during the quarter. Legacy Capital Group California Inc.’s holdings in Bruker were worth $468,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Royal Bank of Canada increased its stake in Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Bruker in the 1st quarter worth about $262,000. Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after buying an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after buying an additional 9,235 shares during the period. Finally, Focus Partners Wealth grew its holdings in Bruker by 115.0% in the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after buying an additional 6,008 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

NASDAQ BRKR opened at $59.83 on Wednesday. The firm has a market capitalization of $9.11 billion, a P/E ratio of -249.29, a P/E/G ratio of 1.89 and a beta of 1.29. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The business’s 50-day simple moving average is $53.80 and its 200-day simple moving average is $45.65.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s payout ratio is currently -83.33%.

Analyst Upgrades and Downgrades

BRKR has been the topic of several recent analyst reports. UBS Group set a $60.00 price objective on shares of Bruker in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Guggenheim upped their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. TD Cowen increased their price target on shares of Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a research note on Thursday, May 7th. Finally, Barclays lifted their price target on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Bruker currently has a consensus rating of “Hold” and an average target price of $56.79.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.